Edwards Lifesciences

“And similar to the Edwards trials, there was some late catch-up in mortality.”

An analyst compares Medtronic CoreValve long-term mortality data to Edwards Lifesciences' TAVR trial results.

“Brooke has most recently led the integration of Edwards Critical Care, which she will continue to oversee as part of her expanded scope.”

Confirms BD's integration of the Critical Care business it acquired from Edwards Lifesciences (now BD's APM segment), a read-through on Edwards having divested that unit.

“the acquisitions of the Edwards Lifesciences' Critical Care Product Group, Parata Systems, Straub Medical, Tepha and others.”

BD lists its acquisition of Edwards Lifesciences' Critical Care Product Group as part of its M&A track record, a divestiture by Edwards as it streamlined its portfolio.

“in early September, we closed the acquisition of Edwards Critical Care, now Advanced Patient Monitoring or APM which contributed $74 million to BD Medical revenue”

BD closed its acquisition of Edwards Lifesciences' Critical Care division (now BD's Advanced Patient Monitoring unit), a divestiture for Edwards that immediately contributed $74 million in revenue to the acquirer.

“one-time charges related to the GennaValve acquisition that did not close as well as litigation expenses”

Edwards' planned acquisition of GennaValve did not close, producing one-time GAAP charges and removing associated spending from the 2026 operating plan.

“the share gain that we had from the Boston Scientific exit contributed a big chunk of that. We are pleased to see the stickiness of that share gain from quarter three to quarter four.”

Boston Scientific's exit from the TAVR market handed Edwards durable share gains, a negative read-through for Boston Scientific's structural-heart franchise.